Peer Reviewed



Background: Peripartum cardiomyopathy and doxorubicin-induced cardiomyopathy are well described conditions but there is little description in the literature of both occurring together.

Case: A 29 year old G1P0 with a remote history of childhood chondroblastic osteosarcoma treated with high-dose doxorubicin therapy who developed minimally symptomatic cardiomyopathy during her pregnancy with ejection fraction reaching as low as 20-30%. She delivered via primary low-transverse cesarean section at 37 weeks complicated by uterine atony with an unremarkable recovery. Cardiomyopathy was treated with metoprolol and enalapril and she achieved ejection fraction of 44% at one year follow-up with complete return to baseline activity.

Discussion: We present a woman with a history of doxorubicin therapy who developed peripartum cardiomyopathy and recovered symptomatically after one year. Although treatment of peripartum cardiomyopathy regardless of etiology is well-defined, there are few reports and no standard guidelines for special considerations in pregnant women with a history of doxorubicin therapy, a topic that may warrant further investigation.


Peripartum cardiomyopathy, doxorubicin, osteosarcoma

Total Pages


Financial Disclosure

The authors report no conflict of interest

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.